Altre lingue HOOKIPA Pharma Inc.

Azioni

HOOK

US43906K1007

Tempo differito Nasdaq Altri mercati azionari 22:00:00 18/04/2024			Variaz. 5gg	Var. 1 gen.
0,7649 ^USD	+0,31%		-5,00%	-5,57%

10/04	HOOKIPA Pharma Inc. annuncia che l'Agenzia Europea dei Medicinali ha concesso la designazione PRIME per il prodotto sperimentale HB-200	CI
22/03	HOOKIPA Pharma Inc. riporta i risultati degli utili per l'intero anno terminato il 31 dicembre 2023	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

HOOKIPA Pharma Announces Grant of Inducement Award under Nasdaq Listing Rule 5635(4)	17/04
HOOKIPA Pharma Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)	16/04
HOOKIPA Pharma to Host Investor Call on HB-200 and Planned Path to Registration	10/04
HOOKIPA Pharma Inc. Announces European Medicines Agency Grant Prime Designation for the Investigational Product HB-200	10/04
HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights	25/03
HOOKIPA Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	22/03
HOOKIPA Pharma Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	22/03
HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights	22/03
North American Morning Briefing : Stocks Struggle After New Records	22/03
North American Morning Briefing : Stock Futures -2-	13/03
HOOKIPA Pharma to Participate in Leerink Partners Global Biopharma Conference	06/03
HOOKIPA Pharma to Cut 30% of Workforce in Restructuring	29/01
HOOKIPA Pharma Provides Update on Business Priorities and Oncology Partnership Programs	29/01
HOOKIPA Pharma Provides Update on Business Priorities and Oncology Partnership Programs	29/01
HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development Organization	17/01
HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development Organization	16/01
HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development Organization	16/01
HOOKIPA Pharma Inc. Announces the Appointment of Mark Winderlich as Chief Development Officer, Effective April 1, 2024	16/01
Top Premarket Gainers	21/12
HOOKIPA Pharma Announces $21.25 Million Equity Investment from Gilead Sciences	21/12

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue HOOKIPA Pharma Inc.

Azioni

HOOK

US43906K1007

Altre lingue

Filtri